Indian Journal of Dermatology (Jan 2015)

Omalizumab-A review

  • Kiran Godse,
  • Aayushi Mehta,
  • Sharmila Patil,
  • Manjyot Gautam,
  • Nitin Nadkarni

DOI
https://doi.org/10.4103/0019-5154.160490
Journal volume & issue
Vol. 60, no. 4
pp. 381 – 384

Abstract

Read online

Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE). The US FDA has approved this molecule for chronic urticaria.

Keywords